Blocking blood flow during pancreatic tumor removal
A Prospective Study of Enucleation of Pancreatic Tumor by Blocking Abdominal Trunk and Superior Mesenteric Artery
This study is testing a new way to remove certain pancreatic tumors while reducing bleeding and protecting healthy tissue in patients with benign or borderline tumors.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 30 (estimated) |
| Ages | 14 Years to 70 Years |
| Sex | All |
| Sponsor | Zhejiang University Academic / other |
| Locations | 1 site (Hangzhou, Zhejiang) |
| Trial ID | NCT06164769 on ClinicalTrials.gov |
What this trial studies
This study evaluates a novel technique for laparoscopic enucleation of pancreatic tumors by blocking the abdominal trunk and superior mesenteric artery to minimize intraoperative bleeding. The approach aims to preserve healthy pancreatic tissue and reduce the risk of tumor recurrence. Conducted at the Second Affiliated Hospital of Zhejiang University, the study will include patients with benign or borderline pancreatic tumors located in the head, neck, or uncinate process of the pancreas. Data on clinical, biochemical, and radiological characteristics will be collected and analyzed throughout the study period from March 2023 to May 2026.
Who should consider this trial
Good fit: Ideal candidates are patients with benign or borderline pancreatic tumors located in the head, neck, or uncinate process of the pancreas.
Not a fit: Patients with highly malignant tumors or those located in the body and tail of the pancreas will not benefit from this study.
Why it matters
Potential benefit: If successful, this method could lead to safer surgical procedures with less blood loss and better preservation of pancreatic function.
How similar studies have performed: While this approach is innovative, similar studies have shown promise in reducing surgical complications associated with pancreatic surgeries.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Benign or borderline tumors diagnosed pathologically, such as pancreatic neuroendocrine tumors, solid pseudopapillary tumors, and cystadenomas, without vascular invasion or distant metastasis * Tumors sited in the pancreatic head, neck, and uncinate process of pancreas * Blockade of both the abdominal trunk and superior mesenteric artery in the laparoscopic enucleation Exclusion Criteria: * Highly malignant pancreatic tumors, or tumors with infiltration or metastasis * Tumors of the body and tail of the pancreas * Transfer to LPD or laparotomy
Where this trial is running
Hangzhou, Zhejiang
- the Second Affiliated Hospital of Zhejiang University — Hangzhou, Zhejiang, China (Recruiting)
Study contacts
- Principal investigator: Bo Zhou, Dr. — The Second Affiliated Hospital, Zhejiang Chinese Medical University
- Study coordinator: Sheng Yan, professor
- Email: shengyan@zju.edu.cn
- Phone: +86-13957161680
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.